Danckert, B.
Christensen, N. L.
Falborg, A. Z.
Frederiksen, H.
Lyratzopoulos, G.
McPhail, S.
Pedersen, A. F.
Ryg, J.
Thomsen, L. A.
Vedsted, P.
Jensen, H.
Article History
Received: 29 March 2022
Accepted: 15 July 2022
First Online: 19 August 2022
Declarations
:
: The study is part of the “Cancer in the Elderly” project, which is registered in the record of processing activities at the Research Unit for General Practice in accordance with Danish guidelines and the general data protection regulation of the European Union. The Danish Clinical Quality Program– National Clinical Registries (RKKP) provided permission to receive and use data from the database of the Danish Breast Cancer Group, the database of the Danish Colorectal Cancer Group, and the Danish Quality Database for Cervical Cancer Screening. According to Danish law, approval by the Committee on Health Research Ethics in the Central Denmark Region was not required as no biomedical intervention was performed. The data used in this study was de-identified (anonymised) before any data handling and analyses.
: N/A.
: Henrik Frederiksen has received project grants from Novartis, Alexion, and Gilead for studies unrelated to this study, and honoraria from Sanofi and Alexion for lectures on TTP/TMA. All other authors declare to have no conflicts of interests.